Seres Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Seres Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $15.00K.
- Seres Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Seres Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Seres Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Seres Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $501.00K.
- Seres Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $877.00K, a 9.21% decline from fiscal 2022.
- Seres Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $966.00K, a 25.64% decline from fiscal 2021.
- Seres Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2021 was $1.30M, a 90.99% decline from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2025-12-31 | $501.00K 10-K · filed 2026-03-12 | |
| 2025-09-30 | $15.00K 10-Q · filed 2025-11-05 | |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $0.00 10-Q · filed 2024-11-13 | |
| 2024-03-31 | $0.00 10-Q · filed 2024-11-13 | |
| 2023-12-31 | $877.00K 10-K · filed 2026-03-12 | |
| 2023-09-30 | $521.00K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $168.00K 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $188.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $966.00K 10-K · filed 2025-03-13 | |
| 2022-09-30 | $429.00K 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $130.00K 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $257.00K 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $1.30M 10-K · filed 2024-03-05 | |
| 2021-09-30 | $174.00K 10-Q · filed 2022-11-02 | |
| 2021-06-30 | $586.00K 10-Q · filed 2022-11-02 | |
| 2021-03-31 | $372.00K 10-Q · filed 2022-11-02 | |
| 2020-12-31 | $14.42M 10-K · filed 2023-03-07 | |
| 2020-09-30 | $12.05M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $15.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $60.00K 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $145.00K 10-K · filed 2022-03-01 | |
| 2019-09-30 | $25.00K 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $120.00K 10-Q · filed 2020-11-09 | |
| 2018-12-31 | $147.00K 10-K · filed 2021-03-02 | |
| 2018-09-30 | $40.00K 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $64.00K 10-Q · filed 2019-11-05 | |
| 2018-03-31 | $32.00K 10-Q · filed 2019-11-05 | |
| 2017-12-31 | $116.00K 10-K · filed 2020-03-02 | |
| 2016-12-31 | $2.14M 10-K · filed 2019-03-06 | |
| 2015-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $93.00K 10-K · filed 2018-03-08 |
| 2015-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | |
| 2014-12-31 | $5.00K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |